Tethys BioScience Inc.
This article was originally published in Start Up
Executive Summary
In diabetes, Tethys BioScience has a commercial objective different than most. Many biotech and pharmaceutical firms are working on drugs to treat the disorder or its side effects, to stave it off or even just reduce the amount of insulin a diabetic needs to inject. Tethys parts from the crowd with a brand-new way of testing for diabetes risk. It aims to thereby capture $500 million in sales annually-at least. The Tethys approach involves a panel of seven biomarkers.